The results from APRIL study, previously presented at the International Stroke Conference 2023, indicate that ApTOLL showed good safety in 151 acute ischemic stroke patients.The article also highlights that the preliminary efficacy results show that ApTOLL significantly reduces mortality and long-term functional dis.